Published in Br J Cancer on May 27, 2008
Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proc Natl Acad Sci U S A (2010) 1.33
Matrix metalloproteinases and gastrointestinal cancers: Impacts of dietary antioxidants. World J Biol Chem (2014) 0.99
The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer. Int J Mol Sci (2012) 0.96
MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. Br J Cancer (2012) 0.88
Hypoxia triggers a Nur77-β-catenin feed-forward loop to promote the invasive growth of colon cancer cells. Br J Cancer (2014) 0.84
Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer. World J Gastrointest Oncol (2011) 0.84
Genetic polymorphisms of matrix metalloproteinases and clinical outcomes in colorectal cancer patients. Int J Med Sci (2013) 0.81
Clinical significance of stromal apoptosis in colorectal cancer. Br J Cancer (2009) 0.80
Transcriptional profiles of host-pathogen responses to necrotic enteritis and differential regulation of immune genes in two inbreed chicken lines showing disparate disease susceptibility. PLoS One (2014) 0.77
Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression. J Control Release (2017) 0.77
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res (1988) 77.80
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation (1999) 2.56
In search of partners: linking extracellular proteases to substrates. Nat Rev Mol Cell Biol (2007) 2.37
Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem (2000) 2.35
The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol (2007) 1.90
Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res (2004) 1.88
Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie (2005) 1.76
Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem (1997) 1.75
Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer (1996) 1.71
Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer (2007) 1.33
Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer (2007) 1.31
92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer (1996) 1.30
Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis (2005) 1.25
Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene (2002) 1.18
Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer (2006) 1.16
Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol (2006) 1.09
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. Gastroenterology (1991) 1.08
Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer (2006) 1.03
A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem Biophys Res Commun (2004) 0.99
Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn J Cancer Res (1997) 0.99
Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer (2003) 0.99
Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis (2007) 0.92
Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis. J Oral Pathol Med (2007) 0.91
T cell-derived matrix metalloproteinase-9 in breast cancer: friend or foe? Breast Dis (2004) 0.88
Association of matrix metalloproteinase-2 and -9 promoter polymorphisms with colorectal cancer in Chinese. Mol Carcinog (2007) 0.87
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis (2010) 6.75
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 4.39
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet (1992) 4.15
High frequency of early colorectal cancer in inflammatory bowel disease. Gut (2008) 3.46
[Pneumocystis pneumonia during infliximab treatment for active Crohn's colitis]. Ned Tijdschr Geneeskd (2005) 2.57
Mortality in hereditary antithrombin-III deficiency--1830 to 1989. Lancet (1991) 2.31
Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut (2008) 2.06
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis (2008) 1.99
Long term serological surveillance after treatment of Helicobacter pylori infection. Gut (1991) 1.90
European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut (2006) 1.87
Optimal resource allocation in colonoscopy: timing of follow-up colonoscopies in relation to adenoma detection rates. Endoscopy (2013) 1.82
Value of serology (ELISA and immunoblotting) for the diagnosis of Campylobacter pylori infection. Digestion (1989) 1.73
Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer (1996) 1.71
CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. Acta Neuropathol (2001) 1.63
Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy (2007) 1.60
An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: the diagnostic approach. Neth J Med (2011) 1.53
Effect of oral zinc supplementation on metallothionein and superoxide dismutase concentrations in patients with inflammatory bowel disease. J Gastroenterol Hepatol (1995) 1.52
Clinical aspects of Crohn's disease of the upper gastrointestinal tract: a comparison with distal Crohn's disease. Am J Gastroenterol (1997) 1.46
Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease--radicals or ridiculous? Aliment Pharmacol Ther (2002) 1.43
Dysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancer. Br J Cancer (2009) 1.40
Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther (2006) 1.32
Veiled cells in chronic idiopathic inflammatory bowel disease. Clin Exp Immunol (1984) 1.29
ELISA assay for quantitative measurement of human immunoglobulins IgA, IgG, and IgM in nanograms. J Immunol Methods (1983) 1.28
Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis (2005) 1.25
Urokinase receptor and colorectal cancer survival. Lancet (1994) 1.18
Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease? Gut (1989) 1.17
Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer (2006) 1.16
Influence of age and Helicobacter pylori infection on serum pepsinogens in healthy blood transfusion donors. Gut (1992) 1.16
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis (2012) 1.15
Crohn's disease of the upper gastrointestinal tract. Neth J Med (1997) 1.14
Superoxide dismutases in gastric and esophageal cancer and the prognostic impact in gastric cancer. Clin Cancer Res (2000) 1.14
Rage signalling promotes intestinal tumourigenesis. Oncogene (2012) 1.11
Superoxide dismutases in relation to the overall survival of colorectal cancer patients. Br J Cancer (1998) 1.10
Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients. Br J Cancer (2007) 1.09
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res (1987) 1.09
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. Gastroenterology (1991) 1.08
Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines. Cancer Res (1990) 1.08
Influence of Helicobacter pylori on reactive oxygen-induced gastric epithelial cell injury. Carcinogenesis (2000) 1.08
Letter to the editor. J Foot Ankle Surg (2013) 1.07
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol (1994) 1.07
Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res (1988) 1.06
Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther (1999) 1.06
Crohn's disease in the elderly: a comparison with young adults. J Clin Gastroenterol (1998) 1.05
Partial defect of neutrophil oxidative metabolism in Crohn's disease. Gut (1984) 1.04
The prognostic role of TGF-β signaling pathway in breast cancer patients. Ann Oncol (2012) 1.04
Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer (2006) 1.03
Differential expression of DHHC9 in microsatellite stable and instable human colorectal cancer subgroups. Br J Cancer (2007) 1.02
Treatment of mesenteric desmoid tumours with the anti-oestrogenic agent toremifene: case histories and an overview of the literature. Eur J Gastroenterol Hepatol (1999) 1.01
Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Biochem J (1997) 1.00
Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis (2010) 1.00
Adult height in patients with early onset of Crohn's disease. Gut (2002) 0.99
Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. Histopathology (1991) 0.99
Gender-related differences in the clinical course of Crohn's disease. Am J Gastroenterol (2001) 0.98
Decreased level of antibodies against Helicobacter pylori in patients with rheumatoid arthritis receiving intramuscular gold. Ann Rheum Dis (1992) 0.98
Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br J Cancer (1997) 0.98
The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther (2013) 0.97
Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis (2007) 0.97
Malignancies in inflammatory bowel disease: fact or fiction? Scand J Gastroenterol Suppl (2002) 0.97
Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br J Cancer (2009) 0.96
Decrease in two intestinal copper/zinc containing proteins with antioxidant function in inflammatory bowel disease. Gut (1991) 0.94
Plasminogen activators in the intestine of patients with inflammatory bowel disease. Thromb Haemost (1988) 0.94
Antibodies to Helicobacter pylori and pepsinogen levels in children from Costa Rica: comparison of two areas with different risks for stomach cancer. Cancer Epidemiol Biomarkers Prev (1993) 0.94
New cytokine therapeutics for inflammatory bowel disease. Cytokine (2004) 0.94
Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer (1996) 0.93
Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut (1993) 0.92
Superoxide dismutases in the human colorectal cancer sequence. J Cancer Res Clin Oncol (1999) 0.91
Crohn's disease of the upper gastrointestinal tract: the value of endoscopic examination. Scand J Gastroenterol Suppl (1998) 0.91
The serological gastric biopsy: a non-endoscopical diagnostic approach in management of the dyspeptic patient: significance for primary care based on a survey of the literature. Scand J Gastroenterol Suppl (2002) 0.91
Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. An evaluation of native blood and plasma assays. Thromb Haemost (1994) 0.91
IgG subclass response to Helicobacter pylori in patients with chronic active gastritis and duodenal ulcer. Scand J Gastroenterol (1992) 0.90
Fecal lysozyme in assessment of disease activity in inflammatory bowel disease. Dig Dis Sci (1998) 0.90
Metallothionein in human gastrointestinal cancer. J Pathol (2000) 0.89
In vivo and in vitro invasion in relation to phenotypic characteristics of human colorectal carcinoma cells. Br J Cancer (1995) 0.89
Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid. Aliment Pharmacol Ther (1988) 0.89
Faecal parameters in the assessment of activity in inflammatory bowel disease. Scand J Gastroenterol Suppl (1999) 0.89